Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.71 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.71 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7473301 | 0.91 | CYP4F2 (0.61) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL2089661 | 0.89 | CYP4F2 (0.68) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL128387 | 0.89 | CYP4F2 (0.72) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL13291593 | 0.89 | CYP4F2 (0.62) | CYP4F2CYP4A11MEP1BMAPTSMN1; SMN2 | |
| SCHEMBL110276 | 0.88 | CYP4F2 (0.65) | CYP4F2CYP4A11CA2CA12CA1 | |
| SCHEMBL129800 | 0.88 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL12035616 | 0.88 | CYP4F2 (0.75) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL4508966 | 0.88 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL2450193 | 0.88 | LOXL2 (0.71) | CYP4F2CYP4A11MEP1BCA2CA12 | |
| SCHEMBL1198044 | 0.88 | CYP4F2 (0.66) | CYP4F2CYP4A11MEP1BCA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9620718-B2 | Method for preparing a semiconducting layer | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2017-04-11 | — | — | US | claimed |
| US-20150188053-A1 | METHOD FOR PREPARING A SEMICONDUCTING LAYER | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2015-07-02 | — | — | US | claimed |
| WO-2013190255-A9 | METHOD FOR PREPARING A SEMICONDUCTING LAYER | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2015-01-08 | — | — | WO | claimed |
| WO-2013190255-A2 | METHOD FOR PREPARING A SEMICONDUCTING LAYER | CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) | 2013-12-27 | — | — | WO | claimed |
| US-8569195-B2 | Internal and external donor compounds for olefin polymerization catalysts II | BASF CORPORATION (US) | 2013-10-29 | — | — | US | claimed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11711971-B2 | Ink composition and method for manufacturing organic light emitting device | LG CHEM, LTD. | 2023-07-25 | — | — | US | disclosed |
| US-11711971-B2 | Ink composition and method for manufacturing organic light emitting device | LG CHEM, LTD. | 2023-07-25 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-1534715-B1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
| EP-1651658-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012326-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-10 | — | — | WO | disclosed |
| EP-0760359-B1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL CO (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5714627-A | REACTING A DIALKYL CARBONATE WITH AN AROMATIC CARBOXYLIC ACID ARYL ESTER IN THE PRESENCE OF A CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0760359-A1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | CYP4F2 3783/4885CYP4A11 3695/4885MEP1B 1645/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | CYP4F2 2749/4885CYP4A11 4355/4885MEP1B 1149/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | CYP4F2 4732/4885CYP4A11 3137/4885MEP1B 348/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | CYP4F2 4794/4885CYP4A11 2858/4885MEP1B 4305/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | CYP4F2 4684/4885CYP4A11 3925/4885MEP1B 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.